Welcome, Guest
Username: Password: Remember me
General
  • Page:
  • 1

TOPIC: Appointment of Dr.Steven Kesten-

Appointment of Dr.Steven Kesten- 05 Mar 2013 23:29 #234

  • wired
  • wired's Avatar Topic Author
  • Offline
  • Fresh Boarder
  • Fresh Boarder
  • Posts: 1
  • Thank you received: 0
This sounds like good news for European market development as well as medical progress of Cytori products

www.evaluatepharma.com/

Cytori Appoints Dr. Steven Kesten as Executive Vice President and Chief Medical Officer

Source News
Company Cytori Therapeutics
Tags Personnel
Date February 26, 2013
SAN DIEGO, Feb. 26, 2013 -- (BUSINESS WIRE) -- Cytori Therapeutics (NASDAQ: CYTX) has appointed Steven Kesten, MD, as Executive Vice President and Chief Medical Officer. In this role, Dr. Kesten will lead global clinical development operations and Cytori’s Medical Affairs activities.

“Dr. Kesten is a seasoned physician executive with more than 30 years of experience in medicine,” said Dr. Hedrick. “This experience includes involvement in high profile clinical trials, leading medical affairs activities, and navigating complex reimbursement environments. Dr. Kesten’s contributions will further strengthen our clinical program, starting with our cardiovascular business and extending to future therapeutic areas.”

Most recently Dr. Kesten served as Vice President and Chief Medical Officer at Uptake Medical, where he oversaw the completion of the VAPOR trial and had medical responsibility for the application that led to the CE Mark approval of Uptake Medical’s device, InterVapor®. He previously served for more than ten years at Boehringer Ingelheim, most recently as the Vice President in Medicine for Marketed Products for respiratory disease. During his tenure, Dr. Kesten was responsible for the development and execution of multiple large-scale clinical trials and took the medical lead in the global registration, branding and reimbursement of the drug Spiriva®, a $3 billion worldwide product for chronic obstructive pulmonary disease. Dr. Kesten lived in Germany for three years and is experienced in European regulatory affairs and reimbursement strategies.

In addition, Dr. Kesten held the position of medical director of the Rush Advanced Lung Disease and Lung Transplant Program at Rush Presbyterian St. Luke’s Medical Center in Chicago. Dr. Kesten received his medical degree and specialty training in internal medicine and pulmonary medicine at the University of Toronto and has more than 160 peer-reviewed publications.

Please Log in or Create an account to join the conversation.

Appointment of Dr.Steven Kesten- 06 Mar 2013 05:28 #235

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3299
  • Thank you received: 1110
Yes- I agree that this man is a welcome addition to the Cytori management.

Has lots of COPD experience, which disorder is known to be a good candidate for be improved by an ADRC therapy- at least I have read quite a lot about that in certain patient boards.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Appointment of Dr.Steven Kesten- 06 Mar 2013 08:58 #236

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2768
  • Thank you received: 199
Fas...I refer to my Spriva post ...LOL

For those interested....I believe ifats had some data on treated COPD patients with encouraging results

Fas...what are your thoughts on the amount of injury with COPD and the volume of ADRC's to effectively treat the disease ? I would think this would be a case where multiple treatments would be of benefit. Again, still justified by the cost COPD patients cost the healthcare system !!!
The following user(s) said Thank You: wired

Please Log in or Create an account to join the conversation.

COPD Report at IFATS 06 Mar 2013 10:16 #238

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3299
  • Thank you received: 1110
Correct Hedge- this is the stuff thats being done at Hospital Angeles in Tijuana, Mexico. BioHeart and others are involved.

the abstract- A MULTICENTER TRIAL TO ASSESS THE SAFETY
AND EFFICACY OF ADIPOSE CELLS IN CONGESTIVE
HEART FAILURE AND CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
Presenter: Kristin Comella, MS
Authors: Comella K, McQuillan S, Lopez J, Perez J,
Parcero J
Bioheart
The Regenerative Medicine Institute (RMI) of Tijuana,
Mexico has partnered with both the Ageless Regenerative
Institute (ARI) and Bioheart to offer a variety of clinical
protocols to patients suffering from degenerative diseases.
In one protocol, developed and executed by RMI and ARI,
patients diagnosed with chronic obstructive pulmonary
disease (COPD) are being treated with adipose or fat derived
stem cells. To date, over 24 patients with COPD have received
an intravenous delivery of the stem cells.
The trial has established a solid safety profile as well as some
early evidence of efficacy. More than 83% of the patients have
demonstrated a statistically significant improvement in their
quality of life. Some of this data includes follow up greater
than 6 months. The average improvement in the St. George’s
Respiratory Questionnaire was 23 points. This represents a
potential new breakthrough for COPD patients who often
suffer from a rapid decline in health after diagnosis. Existing
therapies are designed to target acute symptoms and do not
reverse the effects of the disease or improve the underlying
issues.
In addition to improving the patient’s quality of life, the
treatments showed a marked improvement in their exercise
capacity. Three months after receiving the therapy, the
patients were able to walk on average an additional seventy
meters in their six minute walk test.
RMI and ARI have also partnered with Bioheart to bring
regenerative therapies to cardiac patients. In a protocol
focused on congestive heart failure, more than 15 patients
have been successfully treated using adipose derived stem
cells. The cells are delivered directly into the heart muscle
using a catheter. These patients have demonstrated on
average, an absolute improvement of 13 percentage points
in ejection fraction and an increase of 100 meters in their 6
minute walk distance at their 6 month follow up. This means
that the patient’s hearts appear to be functioning better on
echocardiogram. In addition, the patients have improved
their exercise capacity which allows for a more active and
normal lifestyle.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Appointment of Dr.Steven Kesten- 06 Mar 2013 10:24 #239

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3299
  • Thank you received: 1110
Sorry - forgot your question-

To be perfectly honest- I do not have a clue, what the best treatment protocol would be.
Two-three years back, the Cytori shareholder community was buzzing with all the sensational stuff coming from Dr. Mitsuo, who treated patients (with cells from Celution) with various intractable disorders. COPD was one of them- just know very good results.
New legislation in Japan cracked down on translational stuff like this though and it has gone quiet around the doctor.
The following user(s) said Thank You: myownhedgefund

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.100 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites